NASDAQ:KZR Kezar Life Sciences (KZR) Stock Forecast, Price & News $2.86 +0.08 (+2.88%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$2.73▼$2.8850-Day Range$2.34▼$3.5552-Week Range$2.25▼$11.02Volume431,079 shsAverage Volume878,113 shsMarket Capitalization$207.09 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Kezar Life Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside506.1% Upside$17.33 Price TargetShort InterestHealthy4.06% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.94Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.31) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.58 out of 5 starsMedical Sector103rd out of 983 stocksPharmaceutical Preparations Industry40th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingKezar Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $17.33, Kezar Life Sciences has a forecasted upside of 506.1% from its current price of $2.86.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.06% of the outstanding shares of Kezar Life Sciences have been sold short.Short Interest Ratio / Days to CoverKezar Life Sciences has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kezar Life Sciences has recently decreased by 14.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kezar Life Sciences is -0.85. Previous Next 3.3 News and Social Media Coverage News SentimentKezar Life Sciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for KZR on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.MarketBeat Follows2 people have added Kezar Life Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Kezar Life Sciences is held by insiders.Percentage Held by Institutions84.03% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Kezar Life Sciences are expected to decrease in the coming year, from ($1.31) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kezar Life Sciences (NASDAQ:KZR) StockKezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer. Its product pipeline includes KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.Read More Receive KZR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KZR Stock News HeadlinesMay 31, 2023 | finance.yahoo.comKezar Life Sciences to Participate in the Jefferies Healthcare ConferenceMay 30, 2023 | americanbankingnews.comKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest UpdateJune 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 30, 2023 | americanbankingnews.comKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Down 14.8% in MayMay 18, 2023 | americanbankingnews.comKezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Decrease in Short InterestMay 17, 2023 | americanbankingnews.comFinancial Review: Kezar Life Sciences (NASDAQ:KZR) and Cytokinetics (NASDAQ:CYTK)May 15, 2023 | americanbankingnews.comKezar Life Sciences (NASDAQ:KZR) PT Lowered to $19.00May 15, 2023 | americanbankingnews.comWells Fargo & Company Trims Kezar Life Sciences (NASDAQ:KZR) Target Price to $13.00June 3, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 13, 2023 | marketwatch.com8-K: Kezar Life Sciences, Inc.May 12, 2023 | msn.comWells Fargo Maintains Kezar Life Sciences (KZR) Overweight RecommendationMay 12, 2023 | msn.comHC Wainwright & Co. Maintains Kezar Life Sciences (KZR) Buy RecommendationMay 12, 2023 | msn.comKezar Life Sciences: Q1 Earnings InsightsMay 11, 2023 | seekingalpha.comKezar Life Sciences GAAP EPS of -$0.31May 11, 2023 | finance.yahoo.comKezar Life Sciences Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 1, 2023 | americanbankingnews.comShort Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Expands By 13.2%March 22, 2023 | americanbankingnews.comResearch Analysts Offer Predictions for Kezar Life Sciences, Inc.'s Q1 2023 Earnings (NASDAQ:KZR)March 21, 2023 | americanbankingnews.comKezar Life Sciences, Inc. (NASDAQ:KZR) to Post Q2 2023 Earnings of ($0.28) Per Share, William Blair ForecastsMarch 16, 2023 | msn.comWilliam Blair Downgrades Kezar Life Sciences (KZR)March 16, 2023 | seekingalpha.comKezar sheds 14% after R&D event as William Blair downgradesMarch 14, 2023 | finance.yahoo.comKezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business UpdateMarch 13, 2023 | finance.yahoo.comKezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023March 6, 2023 | finance.yahoo.comKezar Life Sciences to Host Virtual R&D Day on March 22, 2023March 1, 2023 | finance.yahoo.comKezar Life Sciences to Participate in the Cowen 43rd Annual Health Care ConferenceFebruary 23, 2023 | seekingalpha.comKZR Kezar Life Sciences, Inc.January 4, 2023 | finance.yahoo.comKezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | markets.businessinsider.comWells Fargo Reaffirms Their Buy Rating on Kezar Life Sciences (KZR)See More Headlines KZR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZR Company Calendar Last Earnings3/14/2023Today6/03/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KZR CUSIPN/A CIK1645666 Webwww.kezarlifesciences.com Phone(650) 822-5600FaxN/AEmployees56Year FoundedN/APrice Target and Rating Average Stock Price Forecast$17.33 High Stock Price Forecast$20.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+506.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.99% Return on Assets-24.68% Debt Debt-to-Equity Ratio0.04 Current Ratio19.44 Quick Ratio19.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.49 per share Price / Book0.82Miscellaneous Outstanding Shares72,410,000Free Float66,759,000Market Cap$207.09 million OptionableNot Optionable Beta0.16 Key ExecutivesJohn FowlerChief Executive Officer & DirectorMarc L. BelskyChief Financial Officer & SecretaryNoreen Roth HenigChief Medical OfficerPattie ChiangVice President & ControllerAndrea FanVice President-BiologyKey CompetitorsRani TherapeuticsNASDAQ:RANIVerastemNASDAQ:VSTMImmuneeringNASDAQ:IMRXAltimmuneNASDAQ:ALTNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 16,330 shares on 6/1/2023Ownership: 0.023%JPMorgan Chase & Co.Bought 16,424 shares on 5/18/2023Ownership: 1.502%New York State Common Retirement FundSold 14,500 shares on 5/18/2023Ownership: 0.033%Geode Capital Management LLCBought 58,073 shares on 5/16/2023Ownership: 1.429%Susquehanna International Group LLPBought 18,500 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KZR Stock - Frequently Asked Questions Should I buy or sell Kezar Life Sciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KZR shares. View KZR analyst ratings or view top-rated stocks. What is Kezar Life Sciences' stock price forecast for 2023? 3 brokers have issued twelve-month price targets for Kezar Life Sciences' stock. Their KZR share price forecasts range from $13.00 to $20.00. On average, they expect the company's share price to reach $17.33 in the next year. This suggests a possible upside of 506.1% from the stock's current price. View analysts price targets for KZR or view top-rated stocks among Wall Street analysts. How have KZR shares performed in 2023? Kezar Life Sciences' stock was trading at $7.04 at the beginning of the year. Since then, KZR stock has decreased by 59.4% and is now trading at $2.86. View the best growth stocks for 2023 here. Are investors shorting Kezar Life Sciences? Kezar Life Sciences saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 2,940,000 shares, a decrease of 14.8% from the April 30th total of 3,450,000 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio is presently 2.9 days. View Kezar Life Sciences' Short Interest. When is Kezar Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our KZR earnings forecast. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its earnings results on Tuesday, March, 14th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01. What ETFs hold Kezar Life Sciences' stock? ETFs with the largest weight of Kezar Life Sciences (NASDAQ:KZR) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).Direxion Daily S&P Biotech Bull 3x Shares (LABU). What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL). When did Kezar Life Sciences IPO? (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO. What is Kezar Life Sciences' stock symbol? Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR." Who are Kezar Life Sciences' major shareholders? Kezar Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Suvretta Capital Management LLC (9.52%), BlackRock Inc. (6.16%), State Street Corp (4.47%), Sphera Funds Management LTD. (2.61%), Hood River Capital Management LLC (1.98%) and Granahan Investment Management LLC (1.55%). Insiders that own company stock include Equal Talent Investments Ltd, Franklin M Berger, Michael Kauffman and Morningside Venture Investment. View institutional ownership trends. How do I buy shares of Kezar Life Sciences? Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kezar Life Sciences' stock price today? One share of KZR stock can currently be purchased for approximately $2.86. How much money does Kezar Life Sciences make? Kezar Life Sciences (NASDAQ:KZR) has a market capitalization of $207.09 million. The company earns $-68,240,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. How can I contact Kezar Life Sciences? Kezar Life Sciences' mailing address is 4000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.kezarlifesciences.com. The company can be reached via phone at (650) 822-5600 or via email at ceconomides@kezarbio.com. This page (NASDAQ:KZR) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.